MarketCap
Facebook
X
TelegramAnnual report 2025
added 02-20-2026
AbbVie Retained Earnings 2011-2026 | ABBV
Retained earnings — this is the portion of a company’s net profit that has not been distributed to shareholders as dividends but remains at the company’s disposal for future use. It is also referred to as retained income or accumulated earnings.Possible uses include
- reinvestment in development (R&D, equipment, marketing)
- debt repayment
- acquisition of other companies
- creation of reserves for the future
A high level of retained earnings indicates that the company is in a growth phase, accumulating capital and prioritizing reinvestment over dividend payouts. Conversely, low or negative retained earnings may suggest either a generous dividend policy, in which all profits are distributed to shareholders, or ongoing losses that reduce the overall financial result.
The presence of retained earnings does not indicate that the company has available cash — it is solely an accounting figure reflecting the accumulated portion of net profit remaining after dividends have been paid. Therefore, it is important for investors to analyze not only the amount of retained earnings, but also how effectively it is used to develop the business, reduce debt, or build financial stability.
Annual Retained Earnings AbbVie
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -15.5 B | -7.9 B | -1 B | 4.78 B | 3.13 B | 1.06 B | 4.72 B | 3.37 B | 5.46 B | 4.38 B | 2.25 B | 535 M | 1.57 B | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 5.46 B | -15.5 B | 527 M |
Quarterly Retained Earnings AbbVie
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -14.2 B | -11.5 B | -9.53 B | -4.96 B | -3.77 B | -2.38 B | 933 M | 1.79 B | 2.39 B | 4.78 B | 4.95 B | - | 5.1 B | 3.13 B | 1.6 B | 740 M | 2.29 B | 1.06 B | 1.06 B | 1.06 B | 1.06 B | 4.72 B | 4.72 B | 4.72 B | 4.72 B | 3.37 B | 3.37 B | 3.37 B | 3.37 B | 5.46 B | 5.46 B | 5.46 B | 5.46 B | 4.38 B | 4.38 B | 4.38 B | 4.38 B | 2.25 B | 2.25 B | 2.25 B | 2.25 B | 535 M | 535 M | 535 M | 535 M | 1.57 B | 1.57 B | 1.57 B | 1.57 B | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 5.46 B | -14.2 B | 1.56 B |
Retained Earnings of other stocks in the Biotechnology industry
| Issuer | Retained Earnings | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Biohaven Pharmaceutical Holding Company Ltd.
BHVN
|
-2.59 B | $ 9.13 | -0.76 % | $ 591 M |  USA |
 |
MorphoSys AG
MOR
|
-158 M | - | 2.43 % | $ 254 M |  Germany |
 |
I-Mab
IMAB
|
-8.33 B | - | - | $ 866 M |  China |
 |
Midatech Pharma plc
MTP
|
-122 M | - | -18.52 % | $ 27.3 M |  Britain |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
5.24 B | - | - | $ 40.3 B | USA |
 |
Aptorum Group Limited
APM
|
-73.8 M | $ 0.91 | 2.42 % | $ 6.69 M | China |
 |
Edesa Biotech
EDSA
|
-58.6 M | $ 15.52 | -2.39 % | $ 49.6 M | USA |
 |
Biophytis SA
BPTS
|
-17.1 M | - | -13.47 % | $ 169 M |  France |
 |
Genfit SA
GNFT
|
-405 M | - | 2.54 % | $ 160 B | France |
 |
ACADIA Pharmaceuticals
ACAD
|
-2.2 B | $ 22.47 | 1.19 % | $ 3.72 B | USA |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
-108 M | - | -1.52 % | $ 24.7 M | USA |
 |
Applied Molecular Transport
AMTI
|
-366 M | - | - | $ 10.1 M | USA |
 |
Fortress Biotech
FBIO
|
-734 M | $ 2.24 | 0.9 % | $ 62.5 M | USA |
 |
Galectin Therapeutics
GALT
|
-433 M | $ 2.26 | 0.22 % | $ 144 M | USA |
 |
Galapagos NV
GLPG
|
-335 M | $ 28.07 | 0.75 % | $ 2.69 B |  Belgium |
 |
Advaxis
ADXS
|
-197 M | - | -9.65 % | $ 45.9 M | USA |
 |
Grifols, S.A.
GRFS
|
619 M | $ 8.2 | 3.6 % | $ 6.83 B |  Spain |
 |
Harmony Biosciences Holdings
HRMY
|
161 M | $ 31.01 | -0.13 % | $ 1.78 B | USA |
 |
Институт стволовых клеток человека
ISKJ
|
69.4 M | - | - | - |  Russia |
 |
ImmuCell Corporation
ICCC
|
-15.2 M | $ 8.44 | - | $ 76.2 M | USA |
 |
InflaRx N.V.
IFRX
|
-168 M | $ 1.95 | -1.77 % | $ 152 M | Germany |
 |
Immuron Limited
IMRN
|
-68.4 M | $ 0.83 | 3.44 % | $ 6.55 M |  Australia |
 |
Incyte Corporation
INCY
|
214 M | $ 98.87 | -0.23 % | $ 19.3 B | USA |
 |
InMed Pharmaceuticals
INM
|
-101 M | $ 0.71 | 1.28 % | $ 1.74 M |  Canada |
 |
INmune Bio
INMB
|
-209 M | $ 1.35 | 1.5 % | $ 33.4 M | USA |
 |
Innoviva
INVA
|
269 M | $ 23.13 | 0.35 % | $ 1.56 B | USA |
 |
Aeterna Zentaris
AEZS
|
-335 M | - | 5.93 % | $ 314 M | Canada |
 |
AgeX Therapeutics
AGE
|
-63.5 M | - | -10.17 % | $ 12.2 K | USA |
 |
Brainstorm Cell Therapeutics
BCLI
|
-237 M | - | -2.5 % | $ 5.88 M | USA |
 |
BioNTech SE
BNTX
|
-410 M | $ 104.54 | 2.92 % | $ 27.2 B | Germany |
 |
Aeglea BioTherapeutics
AGLE
|
-1.13 B | - | - | $ 1.01 B | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
-308 M | - | - | $ 26.5 M | USA |
 |
AIkido Pharma
AIKI
|
-268 M | - | 1.93 % | $ 17.4 M | USA |
 |
Jaguar Health
JAGX
|
-400 M | $ 7.55 | -4.13 % | $ 17.6 M | USA |
 |
KalVista Pharmaceuticals
KALV
|
-763 M | $ 26.67 | -0.02 % | $ 1.44 B | Britain |
 |
Akero Therapeutics
AKRO
|
-826 M | - | - | $ 3.67 B | USA |
 |
Innate Pharma S.A.
IPHA
|
-220 M | $ 1.43 | -4.03 % | $ 235 M | France |
 |
Kamada Ltd.
KMDA
|
-43.9 M | $ 8.15 | 0.49 % | $ 260 M |  Israel |
 |
Akouos
AKUS
|
-168 M | - | 0.23 % | $ 488 M | USA |
 |
Allakos
ALLK
|
-1.12 B | - | - | $ 28.6 M | USA |
 |
Kazia Therapeutics Limited
KZIA
|
-68.3 M | $ 13.24 | 6.56 % | $ 1.75 B | Australia |
 |
AlloVir
ALVR
|
-160 M | - | 4.14 % | $ 49.1 M | USA |
 |
Ligand Pharmaceuticals Incorporated
LGND
|
499 M | $ 223.98 | -0.39 % | $ 4.1 B | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
-176 M | $ 3.22 | 7.69 % | $ 5.3 M | Israel |
 |
Liquidia Corporation
LQDA
|
-626 M | $ 38.39 | 0.62 % | $ 3.3 B | USA |
 |
Ampio Pharmaceuticals
AMPE
|
-243 M | - | -11.43 % | $ 502 K | USA |
 |
CureVac N.V.
CVAC
|
-1.06 B | - | - | $ 867 M | Germany |
 |
Applied Therapeutics
APLT
|
-469 M | - | - | $ 8.42 M | USA |
 |
Aptose Biosciences
APTO
|
-566 M | - | -45.71 % | $ 1.2 M | Canada |
 |
Aquestive Therapeutics
AQST
|
-447 M | $ 4.08 | 0.74 % | $ 436 M | USA |